TY - JOUR
T1 - High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma
T2 - An international extranodal lymphoma study group and intergruppo Italiano linfomi study
AU - Mian, Michael
AU - Gaidano, Gianluca
AU - Conconi, Annarita
AU - Tsang, Richard
AU - Gospodarowicz, Mary K.
AU - Rambaldi, Alessandro
AU - Rossi, Andrea
AU - Oldani, Elena
AU - Federico, Massimo
AU - Luminari, Stefano
AU - Bellei, Monica
AU - Pogliani, Enrico M.
AU - Rossini, Fausto
AU - Cabrera, Maria Elena
AU - Martelli, Maurizio
AU - Lopez-Guillermo, Armando
AU - Busetto, Mario
AU - Cavalli, Franco
AU - Zucca, Emanuele
AU - Cortelazzo, Sergio
N1 - Funding Information:
The work was supported by the Autonomous Province of Bolzano, the local health authority, and Alto Adige Bolzano-AIL Onlus. The authors thank Dearbhla Duffy for providing advice.
PY - 2011/5
Y1 - 2011/5
N2 - The impact of different treatment modalities and prognostic factors on the clinical course of primary thyroid diffuse large B-cell lymphoma (PTDLBCL) is still the subject of research. This study was conducted to clarify these clinical aspects of this disorder. The clinical parameters of 48 patients with PTDLBCL at time of diagnosis were comparable to those of previous studies. Patients underwent either radiotherapy (RT) ±° surgery (SX), chemotherapy (CHT) alone or in combination with local treatments (RT or SX), or SX followed by CHT and RT. A 90% complete remission (CR) rate was observed among patients who underwent combined treatment modalities (CTM), compared to 76% among the others. The 5-year progression-free survival differed significantly between both groups (p = 0.028). Poor performance status and advanced age correlated with decreased survival. PTDLBCL is a curable disease prevalent in elderly patients. Combined treatment modalities were able to induce an elevated rate of CR, improving long-term survival in younger patients. However, the outcome in elderly patients still remains unsatisfactory.
AB - The impact of different treatment modalities and prognostic factors on the clinical course of primary thyroid diffuse large B-cell lymphoma (PTDLBCL) is still the subject of research. This study was conducted to clarify these clinical aspects of this disorder. The clinical parameters of 48 patients with PTDLBCL at time of diagnosis were comparable to those of previous studies. Patients underwent either radiotherapy (RT) ±° surgery (SX), chemotherapy (CHT) alone or in combination with local treatments (RT or SX), or SX followed by CHT and RT. A 90% complete remission (CR) rate was observed among patients who underwent combined treatment modalities (CTM), compared to 76% among the others. The 5-year progression-free survival differed significantly between both groups (p = 0.028). Poor performance status and advanced age correlated with decreased survival. PTDLBCL is a curable disease prevalent in elderly patients. Combined treatment modalities were able to induce an elevated rate of CR, improving long-term survival in younger patients. However, the outcome in elderly patients still remains unsatisfactory.
KW - DLBCL
KW - lymphoma
KW - thyroid
KW - treatment
UR - http://www.scopus.com/inward/record.url?scp=79955067625&partnerID=8YFLogxK
U2 - 10.3109/10428194.2011.555888
DO - 10.3109/10428194.2011.555888
M3 - Article
SN - 1042-8194
VL - 52
SP - 823
EP - 832
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 5
ER -
